Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:337

Article

Ulander, Lotta¹  Tolppanen, Heli¹  Hartman, Otto¹  Rissanen, Tuomas T.²  Paakkanen, Riitta¹  Kuusisto, Jouni¹  Anttonen, Olli³  Nieminen, Tuomo³  Yrjola, Jaana⁴  Ryysy, Ransu⁴  Drews, Teemu⁵  Utriainen, Seppo⁵  Karjalainen, Pasi¹  Anttila, Ismo⁶  Nurmi, Katariina⁷  Silventoinen, Kristiina⁷  Koskinen, Miika⁸  Kovanen, Petri T.⁹  Lehtonen, Jukka¹  Eklund, Kari K.⁷  Sinisalo, Juha¹ 

[1] Univ Helsinki, Helsinki Univ Hosp, Heart & Lung Ctr, Meilahti Tower Hosp,PL 340, Helsinki 00029, Finland

[2] North Karelia Cent Hosp, Ctr Heart, Joensuu, Finland

[3] Paijat Hame Cent Hosp, Dept Internal Med, Lahti, Finland

[4] Kymenlaakson Cent Hosp, Dept Internal Med, Kotka, Finland

[5] South Karelia Cent Hosp, Dept Internal Med, Lappeenranta, Finland

[6] Seinajoki Cent Hosp, Dept Internal Med, Seinajoki, Finland

[7] Univ Helsinki, Helsinki Univ Hosp, Dept Rheumatol, ORTON Orthopaed Hosp,Orton Fdn, Helsinki, Finland

[8] Univ Helsinki, Helsinki Univ Hosp, Helsinki Biobank, Helsinki, Finland

[9] Wihuri Res Inst, Biomedicum, Helsinki, Finland

关键词: Myocardial infarction;    ST-elevation myocardial infarction;    Non-ST-elevation myocardial infarction;    Hydroxychloroquine;    Inflammation;    Interleukins;   

DOI  :  10.1016/j.ijcard.2021.04.062

来源: Elsevier

【 摘 要 】

Objectives: To determine the anti-inflammatory effect and safety of hydroxychloroquine after acute myocardial infarction. Method: In this multicenter, double-blind, placebo-controlled OXI trial, 125 myocardial infarction patients were randomized at a median of 43 h after hospitalization to receive hydroxychloroquine 300 mg (n = 64) or placebo (n = 61) once daily for 6 months and, followed for an average of 32 months. Laboratory values were measured at baseline, 1, 6, and 12 months. Results: The levels of interleukin-6 (IL-6) were comparable at baseline between study groups (p = 0.18). At six months, the IL-6 levels were lower in the hydroxychloroquine group (p = 0.042, between groups), and in the on-treatment analysis, the difference at this time point was even more pronounced (p = 0.019, respectively). The high-sensitivity C-reactive protein levels did not differ significantly between study groups at any time points. Eleven patients in the hydroxychloroquine group and four in the placebo group had adverse events leading to in-terruption or withdrawal of study medication, none of which was serious (p = 0.10, between groups). Conclusions: In patients with myocardial infarction, hydroxychloroquine reduced IL-6 levels significantly more than did placebo without causing any clinically significant adverse events. A larger randomized clinical trial is warranted to prove the potential ability of hydroxychloroquine to reduce cardiovascular endpoints after myocar-dial infarction. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).

【 授权许可】

Free